Hospira's Second Biosimilar Approval In The EU

BMI Core View: The biosimilar sector will become increasingly competitive, however, only firms with strong marketing capabilities will capture its vast potential. BMI views biosimilars as an area with great potential for returns in the non-innovative pharmaceutical sector. Relatively limited competition compared with the traditional small molecule generics sector, the ability to offer large absolute price reductions against originator firms and the retention of strong margins are key positives for the industry.

To read the full article, please choose one of the following options: